Please assess the completion status of the following clinical trial:

Trial Title: Effect of Tenofovir/Emtricitabine in Patients Recently Infected With SARS-COV2 (Covid-19) Discharged Home

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients 18 years and over~* SARS-CoV2 Infection confirmed by PCR~* Patients who do not require immediate hospitalization~* Signed informed consent~Non-Inclusion criteria:~* Patients with HIV or Hepatitis B~* Symptoms suggestive of a SARS-CoV2 infection that has been progressing for more than 7 days~* Asympomatic patients with unknown date of infection or date of infection\>7 days~* Chronic HCV infection~* Contraindication to the use of TDF/FTC~* Hypersensitivity to tenofovir, to emtricitabine or to any of the excipients (especially lactose)~* Glomerular filtration rate \<80mL / min~* Recent (less than 7 days) or concomitant use of NSAIDs or other nephrotoxic drugs (antiinfectives, immunosuppressants, allopurinol, lithium~* need for hospitalization for contemporary decompensation of a comorbidity~* need for hospitalization due to SARS-CoV2 infection:~* Capillary oximetry less than 95%~* clinical evaluation by the investigating doctor leading to hospitalization~* Pregnant or breastfeeding women~Exclusion Criteria:~- Diagnosis of pregnancy during treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TDF / FTC (Type: EXPERIMENTAL): 2 tablets on Day-1 then 1 tablet/day for 6 days
- usual care (Type: NO_INTERVENTION): Standard of Care

Based on this trial design, predict the completion outcome and termination type (if applicable).